Send to

Choose Destination
N Engl J Med. 2017 Mar 16;376(11):1047-1053. doi: 10.1056/NEJMoa1609583.

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

Author information

From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).


Adipose tissue-derived "stem cells" have been increasingly used by "stem-cell clinics" in the United States and elsewhere to treat a variety of disorders. We evaluated three patients in whom severe bilateral visual loss developed after they received intravitreal injections of autologous adipose tissue-derived "stem cells" at one such clinic in the United States. In these three patients, the last documented visual acuity on the Snellen eye chart before the injection ranged from 20/30 to 20/200. The patients' severe visual loss after the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, or lens dislocation. After 1 year, the patients' visual acuity ranged from 20/200 to no light perception.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center